Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients

Xy, Dong; Xa, Yang; Yd, Wang; Wf, Chen

doi:10.1038/sj.bjc.6602138

Cited by 35 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially in the case of CAGE, CTAGE, FTHL17, ZNF165, AKAP3 and SLLP1 we observed significant mRNA expression in the vast majority of CT Antigen Expression in Head and Neck Cancer healthy tissue specimen. Interestingly, the latter three of these genes all belong to a group of only very recently discovered new "CT" antigens [35][36][37] the expression of which has, so far, not extensively been analyzed in larger numbers of malignant and non-malignant tissues.…”

Section: Discussionmentioning

confidence: 99%

“…Reverse transcription was run at 42˚C for 45 min with heat inactivation of the enzyme at 95˚C for 5 min. PCR primers and conditions used for the analysis of AKAP3, ZNF165, SLLP1, and NY-TLU-57 were those described in the corresponding primary publications [35][36][37] (see also Table 1). Analysis of the remaining antigens was performed according to PCR conditions published in the CT Gene database of the Academy of Cancer immunology (http://www.cancerimmunity.org/ CTdatabase/) (see also Table 1).…”

Section: Patients and Tissuesmentioning

confidence: 99%

See 1 more Smart Citation

Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma

Atanackovic¹,

I²,

Cao³

et al. 2006

Cancer Biology & Therapy

View full text Add to dashboard Cite

Cancer-Testis (CT) antigens are by definition expressed in tumor but not in healthy tissue except testis and might represent ideal targets for antigen-specific immunotherapy. Here, we present the first comprehensive analysis of CT antigen expression in patients with head and neck squamous cell carcinoma (HNSCC). Tumor samples (N = 51), and adjacent healthy tissue from patients with HNSCC were analyzed for the expression of 23 genes designated CT antigens using RT-PCR. Patient sera (N = 39) were screened for IgG antibody responses against NY-ESO-1, MAGEA3, and SSX2. According to their expression pattern antigens were divided into four groups. ADAM2, LIP1, SLLP1, AKAP3, CTAGE, ZNF165, CAGE, and FTHL17 were expressed in tumor and healthy tissue at comparable frequencies. NY-TLU-57, GAGE1, SAGE1 were expressed more frequently in tumor samples than in healthy tissues. TPTE, LDHC, SPO11 were expressed neither in tumor samples nor in healthy tissue. 9 CT antigens were expressed only in the tumor tissue and may represent ideal candidates for active immunotherapy in HNSCC: MAGEA3 was expressed in 72%, SSX1 in 45%, MAGEC2 in 33%, MAGEC1 in 28%, BAGE in 17%, SSX2 in 16%, SCP1 in 12%, NY-ESO-1 in 6%, and HOM-TES-85 in 4% of cases. 86% of tumor samples expressed at least one, 69% expressed at least two, and 43% expressed at least three of these antigens. Three patients showed an antibody response against NY-ESO-1. In conclusion, we demonstrate here that HNSCC frequently express CT antigens. Furthermore, a relatively high percentage of tumors express more than one CT antigen opening the perspective for polyvalent antigen-specific immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Patients and Tissuesmentioning

confidence: 99%

Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma

Atanackovic¹,

I²,

Cao³

et al. 2006

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Transcription factors are the principal regulator genes expressed in tumorigenesis once their function or expression pattern is altered (Dong et al, 2004;Wang et al, 2009). As a ZNF protein containing a C-terminal domain with 13 conserved C2H2-type ZNF motifs, ZFX may function in the transcriptional regulation as well as tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

Regulation of cell proliferation and migration in gallbladder cancer by zinc finger X-chromosomal protein

Tan

Zhang

et al. 2013

Gene

View full text Add to dashboard Cite

“…In the last few years, several CT antigens have been identified in our lab using these free but precious online resources [63][64][65]. Interestingly, the usage of this strategy is not only limited to the discovery of tumor antigens, but also applied to tumor marker discovery.…”

Section: Box 1 Characteristics Of Ct Antigensmentioning

confidence: 98%

Developing effective tumor vaccines: basis, challenges and perspectives

Chen

2007

Front. Med. China

View full text Add to dashboard Cite

A remarkable advance in tumor immunology during the last decade is the elucidation of the antigenic basis of tumor recognition and destruction. A variety of tumor antigens have been identified using several strategies including conventional experiments and newly developed bioinformatics. Among these antigens, cancer/testis antigen (CT antigen) is considered to be the most promising target for immunotherapy by vaccination. Successful immunotherapy of tumors requires understanding of the natural relationship between the immune system and tumor in the status of differentiation, invasion and maturation. Continued progress in development of effective cancer vaccines depends on the identification of appropriate target antigens, the establishment of optimal immunization strategies without harmful autoimmune responses and the ability of manipulating tumor microenvironment to circumvent immune suppression and to augment the anti-tumor immune response.

show abstract

Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients

Cited by 35 publications

References 17 publications

Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma

Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma

Regulation of cell proliferation and migration in gallbladder cancer by zinc finger X-chromosomal protein

Developing effective tumor vaccines: basis, challenges and perspectives

Contact Info

Product

Resources

About